IGC Pharma (IGC) Return on Capital Employed (2011 - 2025)
IGC Pharma (IGC) posted quarterly Return on Capital Employed of 110.45% for Q3 2025, up 1096.0% year-over-year from 9.24% in Q3 2024, and down 5.12% quarter-over-quarter from 105.08% in Q2 2025.
IGC Pharma (IGC) Return on Capital Employed (2011 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Return on Capital Employed for 15 consecutive years, with 110.45% the latest figure, recorded in Q3 2025.
- In Q3 2025, Return on Capital Employed rose 1096.0% year-over-year to 110.45%; the TTM figure through Sep 2025 stood at 110.45% (up 1096.0% YoY), while the FY2026 annual figure was 40.34%, up 6501.0% from the prior year.
- Return on Capital Employed fell to 110.45% in Q3 2025 per IGC's latest filing, from 105.08% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27.2% in Q2 2021 and bottomed at 129.59% in Q2 2024.
- Historically, Return on Capital Employed has averaged 80.53% across 5 years, with a median of 76.56% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 5303 bps — and 2025, when it surged 2452 bps.
- IGC Pharma's Return on Capital Employed stood at 37.46% in 2021, then slumped by 91 bps to 71.57% in 2022, then sank by 36 bps to 97.66% in 2023, then retreated by 19 bps to 116.1% in 2024, then advanced by 5 bps to 110.45% in 2025.
- Business Quant data shows IGC's Return on Capital Employed at 110.45% in Q3 2025, 105.08% in Q2 2025, and 111.89% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -110.45% |
| Jun 30, 2025 | -105.08% |
| Mar 31, 2025 | -111.89% |
| Dec 31, 2024 | -116.10% |
| Sep 30, 2024 | -121.41% |
| Jun 30, 2024 | -129.59% |
| Mar 31, 2024 | -118.90% |
| Dec 31, 2023 | -97.66% |
| Sep 30, 2023 | -78.29% |
| Jun 30, 2023 | -76.56% |
| Mar 31, 2023 | -69.39% |
| Dec 31, 2022 | -71.57% |
| Sep 30, 2022 | -65.39% |
| Jun 30, 2022 | -67.26% |
| Mar 31, 2022 | -57.96% |
| Dec 31, 2021 | -37.46% |
| Sep 30, 2021 | -36.29% |
| Jun 30, 2021 | -27.20% |
| Mar 31, 2021 | -31.55% |
| Dec 31, 2020 | -35.89% |